A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating ...

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Two new Omicron subvariants are gaining ground in the U.S. as some people report experiencing respiratory symptoms like ...

Safe dividend-paying income stocks trading under $30 are passive income home runs. Stocks trading under the $30 level offer Boomers a larger share count when they buy. With the geopolitical ...

PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.

Q: I live in a retirement community and have noticed that while some neighbors seem to have mild trouble with remembering ...

The expensive medication does little to prevent hospitalisation or death for people who are vaccinated against the virus, a ...

Adriana Alatorre was in peak condition, running at least 30 miles a week before a mild bout of COVID knocked her off her feet ...

Pfizer’s stock is catching a cold, slipping $0.24 to land near $24.16 while option traders wrap themselves in bearish ...

Pfizer’s stock slid a modest $0.20 to $24.34, despite option activity showing more bullish call buyers than sellers. Implied ...

Q: I’m achy and tired a lot and my doctor said it comes from chronic inflammation. What is that exactly and how can I get it ...